Candesartan cilexetil in children with hypertension or proteinuria: preliminary data
2006; Springer Science+Business Media; Volume: 21; Issue: 10 Linguagem: Inglês
10.1007/s00467-006-0144-0
ISSN1432-198X
AutoresGiacomo D. Simonetti, Rodo O. von Vigier, Martin Konrad, Mattia Rizzi, Emilio Fossali, Mario G. Bianchetti,
Tópico(s)Hormonal Regulation and Hypertension
ResumoThe angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood. We were impressed by the neutral taste and the small size of the candesartan cilexetil tablets. This angiotensin II receptor blocker was used during 4 months in 17 pediatric patients (aged 0.5–16, median 4.5 years) with chronic arterial hypertension (n=6), overt proteinuria (n=2), or both (n=9). The initial candesartan dose of 0.23 (0.16–0.28) mg/kg body weight once daily (median and interquartile ranged) was doubled in ten patients [final dose 0.35 (0.22–0.47) mg/kg body weight]. No adverse clinical experiences were noted on candesartan. Candesartan increased plasma potassium by 0.3 (0.0–0.8) mmol/l (P<0.01). In children with arterial hypertension, blood pressure decreased by 9 (3–13)/9 (3–18) mmHg (P<0.01); in those with overt proteinuria the urinary albumin/creatinine ratio decreased by 279 (33–652) mg/mmol (P<0.05). In conclusion, in children candesartan reduces blood pressure and proteinuria with an excellent short-term tolerability profile.
Referência(s)